Jump to main content.


Benzo[a]pyrene (BaP) Quickview (CASRN 50-32-8)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Benzo[a]pyrene (BaP)

File First On-Line: 03/31/1987; Last Significant Revision: 07/01/1992

Category (section)
Status
Last Revised
Oral RfD Assessment No data
Inhalation RfC Assessment No data
Carcinogenicity Assessment On-line 11/01/1994
Under Re-Assessment
Synonyms
  • 50-32-8
  • BAP
  • Benzo[a]pyrene
  • Benzo(d,e,f)chrysene
  • 3,4-Benzopirene
  • 3,4-Benzopyrene
  • 6,7-Benzopyrene
  • Benzo(a)pyrene
  • 3,4-Benzpyren
  • 3,4-Benzpyrene
  • 3,4-Benz(a)pyrene
  • more...
Benzo[a]pyrene (BaP) Source Documents
Revision History
Date Section Description
04/01/1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Not Assessed under the IRIS Program.

Top of page


Reference Concentration for Chronic Inhalation Exposure (RfC)

Not Assessed under the IRIS Program.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals)
  • Weight-of-Evidence Narrative:
    • Human data specifically linking benzo[a]pyrene (BAP) to a carcinogenic effect are lacking. There are, however, multiple animal studies in many species demonstrating BAP to be carcinogenic following administration by numerous routes. BAP has produced positive results in numerous genotoxicity assays.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

Oral Slope Factor(s)
Extrapolation Method
7.3 per mg/kg-day Risk estimate based on a geometric mean of four slope factors obtained by different modeling procedures
Drinking Water Unit Risks
2.1x10-4 per µg/L
Risk Level
Concentration
E-4 (1 in 10,000) 5x10-1 µg/L
E-5 (1 in 100,000) 5x10-2 µg/L
E-6 (1 in 1,000,000) 5x10-3 µg/L
  • Dose-Response Data (Carcinogenicity, Oral Exposure)
    • Tumor Type: Forestomach, squamous cell papillomas and carcinomas; forestomach, larynx and esophagus, papillomas and carcinomas (combined)
    • Test Species: CFW mice, sex unknown; SWR/J Swill mice; Sprague-Dawley rats, males and females
    • Route: Oral, Diet
    • Reference: Neal and Rigdon, 1967; Rabstein et al., 1973; Brune et al., 1981

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

  • Not Assessed under the IRIS Program.

Top of page


Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research


Local Navigation


Jump to main content.